Breaking AI & Tech News Analyzed

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

Science is often seen as a dry and serious field, but does it have to be? A recent study published in Proceedings of the Royal Society B found that scientists deliver an average of only 1.6 jokes per presentation, with 66% generating only polite chuckles.The findings confirm previous research, including a randomized clinical trial conducted over 20 years ago by Timandra Harkness and Helen Pilcher under the guise of the Comedy Research Project. The study found that laughter levels failed to reach statistical significance, even when scientists attempted to incorporate humor into their talks.However, research suggests that humor can be an effective tool in science communication. A 2025 study called Wit Meets Wisdom found that humor can boost credibility and likability, making researchers seem more trustworthy and their findings less likely to be disputed.Helen Pilcher, a science writer and author, argues that scientists should not be afraid to adopt a more playful tone when communicating their research. By incorporating humor, scientists can build cohesion and foster a sense of shared perspective with their audience.Pilcher suggests that scientists can use humor to make their research more engaging and memorable, without having to convert it into standup comedy. By doing so, scientists can make their research more accessible and enjoyable for a wider audience.

Robert F Kennedy Jr, the US health secretary, has unveiled a chaotic and unpredictable agenda for public health policy under his 'Make America Healthy Again' (Maha) initiative. His approach tends to favor personal choice and autonomy over large-scale, mandatory public health interventions, such as childhood vaccine requirements.The Maha agenda has raised concerns over the potential risks associated with injectable peptide drugs. Mr. Kennedy plans to open up the sale of 'about 14' of these drugs to the public, despite the US Food and Drug Administration (FDA) restricting 17 peptides in 2023 due to 'potential significant safety risks'. None of these peptides have been proven to be safe or effective for human use.The peptides in question are often promoted for biological enhancement, such as increasing muscle mass or cognitive benefits, but the evidence for these effects in humans is thin. Reports of people self-administering peptide therapies, usually bought from China 'for research use only', are widespread, particularly in Silicon Valley.The Maha project wants to make the grey market the only market, effectively sanctioning mass public use of unproven treatments. Peptides are clearly drugs and shouldn’t be allowed for widespread use without rigorous clinical trials. Opening loopholes for sale would undermine the precautionary principle that has successfully led public health policy for generations.It is also worth noting that other governments are unlikely to be as cavalier as Mr. Kennedy about peptides. However, people everywhere will continue to call for more personal choice and more bodily autonomy, and those conversations are important. The case for safety, proof, and regulation must be made to ensure that public health policy prioritizes the well-being of individuals.